5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

Jan. 17

Weekly Gain

Control4  (NASDAQ: CTRL  )

$27.79

46%

Tesla Motors (NASDAQ: TSLA  )

$170.01

17%

Celldex Therapeutics  (NASDAQ: CLDX  )

$28.32

16%

SolarCity  (NASDAQ: SCTY  )

$75.11

12%

Bazaarvoice  (NASDAQ: BV  )

$7.81

11%

Source: Barron's.

Let's start with Control4. The stock of the home-automation specialist surged higher after Nest Labs agreed to be acquired in a $3.2 billion deal. If the company behind the Nest Learning Thermostat is good enough to sell for billions, the logic here is that another tech titan will want to keep up by adding Control4 to its arsenal as the smart home becomes the next battleground.

Tesla Motors shares were recharged after the electric-car maker announced that it wound up delivering 6,900 Model S sedans during the holiday quarter. Back in November it was only targeting production of slightly less than 6,000 vehicles.

Celldex Therapeutics moved higher after making the cut for Cantor Fitzgerald's 10 stocks to buy in 2014. A drug status update next month could be a major catalyst. Cantor Fitzgerald has a $39 price target on the shares.

SolarCity shares got brighter after Deutsche Bank initiated coverage of the solar-panel installer with a "buy" rating. Deutsche Bank established a price target of $90, setting a scenario where the stock can dramatically exceed that if favorable pricing and financing factors fall into place.

Finally, we have Bazaarvoice moving higher. The social e-commerce specialist bounced back after getting slammed a week earlier when a U.S. court ruled that Bazaarvoice's acquisition of a rival two years ago violated the country's antitrust law.

Keep the good vibes coming
If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

DocumentId: 2800838, ~/Articles/ArticleHandler.aspx, 4/20/2014 3:23:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement